Antibiotice gains ground on cardiovascular segment

Antibiotice, one of the leading local drug producers, saw 10 million RON (3 million euros) in sales on the cardiovascular drugs segment in 2007, up 67% on 2006. The cardiovascular segment was the company’s best performing amid a 4% decline for anti-infective drugs (which include antibiotics). The cardiovascular drugs market, which reached 1.2 billion RON last year (366.5 million euros), is the most valuable market in the pharmaceutical industry and one of the most competitive, given that the other local producers have a solid presence on this segment. Antibiotice entered this market in 2006, and launched an additional seven products last year. The traditional area where Antibiotice operates, anti-infective drugs, fetched revenues worth 102 million RON (30.5 million euros), i.e. 55% of turnover. On this segment, Antibiotice has a 12% market share. “These results were triggered by the drugs introduced in the company’s portfolio over the last few years, such as Cefort, Ceftamil, AmpiPlus, and AmoxiPlus,” the company’s report also reads.